Report overview
Bio-Therapeutic Glycoproteins are bioactive compounds with carbohydrates attached to proteins. Glycan is the specific site where carbohydrate attaches to proteins and process of production is called glycosylation. Bio-therapeutic glycoproteins produced with glycan moieties that are similar to natural mammal glycans. The most common types are glycosylation O-linked and N-linked that are mainly depends on protein sequence attachment. Carbohydrates linked to proteins through either ? and ? linkages. Glycosylation is an important process of bio-therapeutic glycoproteins because it is critically modulated into bioactivity, stability, solubility against proteolysis, yield, clearance rate from circulation and immunogenicity. The bio-therapeutic glycoproteins mainly produced by yeast expression systems, insect cells, mammalian systems, and plant-based expression systems. In yeast expression systems, yeast is cultured chemically to scale up fermentation to an industrial level. Yeast and human share same N-glycan's linkage. Insect cells represent an alternative system for expression of recombinant bio-therapeutic proteins. Later recombinant proteins are separated from insect cells. Mammalian Systems are used to produce complex bio-therapeutic glycoproteins. Most of the FDA approved bio-therapeutic glycoproteins derived from mammalian systems. Plant-based expression systems used for the scale-up production of glycoproteins. Among all systems, mammalian systems are well established in pharmaceuticals. Some examples of bio-therapeutic glycoproteins include tocilizumab, bevacizumab, adalimumab, etc.
This report aims to provide a comprehensive presentation of the global market for Bio-Therapeutic Glycoproteins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bio-Therapeutic Glycoproteins. This report contains market size and forecasts of Bio-Therapeutic Glycoproteins in global, including the following market information:
Global Bio-Therapeutic Glycoproteins Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Bio-Therapeutic Glycoproteins Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Bio-Therapeutic Glycoproteins companies in 2022 (%)
The global Bio-Therapeutic Glycoproteins market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The potential benefits of Bio-Therapeutic Glycoproteins have been a subject of rising industrial interest in the context of wide range application. So, far they include several protein classes like antisera, cytokines, clotting factors, hormones, enzymes and enzyme inhibitors have been best suited physiologically. The trend of industrial developments likely continues alongside with growing knowledge about the functions of bio-therapeutic glycoproteins. Bio-Therapeutic Glycoproteins are a fastest growing field in the pharmaceutical industry due to a wide range of applicability. The mammalian expression system is used to produce glycoproteins that coded with human-like glycans. Bio-Therapeutic glycoproteins represent an integrated treatment for most of the autoimmune disorders, cancers, replacement therapies like hormone and enzyme substituted. All these benefits of glycoproteins drive the robust growth of the Bio-Therapeutic Glycoproteins market.
We surveyed the Bio-Therapeutic Glycoproteins manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bio-Therapeutic Glycoproteins Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Bio-Therapeutic Glycoproteins Market Segment Percentages, by Type, 2022 (%)
Antisera
Cytokines
Clotting Factors
Hormones
Enzymes
Enzyme Inhibitors
Global Bio-Therapeutic Glycoproteins Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Bio-Therapeutic Glycoproteins Market Segment Percentages, by Application, 2022 (%)
Oncology and Haematology
Diabetes
Cardiology
Inflammatory Diseases
Others
Global Bio-Therapeutic Glycoproteins Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Bio-Therapeutic Glycoproteins Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bio-Therapeutic Glycoproteins revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Bio-Therapeutic Glycoproteins revenues share in global market, 2022 (%)
Key companies Bio-Therapeutic Glycoproteins sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Bio-Therapeutic Glycoproteins sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Genentech
Hoffmann-La Roche
Genzyme Corp
Abbott Laboratories
Amgen
Biogen
Merck
GlaxoSmithKline
Novartis Pharmaceuticals Corp
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bio-Therapeutic Glycoproteins, market overview.
Chapter 2: Global Bio-Therapeutic Glycoproteins market size in revenue and volume.
Chapter 3: Detailed analysis of Bio-Therapeutic Glycoproteins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bio-Therapeutic Glycoproteins in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Bio-Therapeutic Glycoproteins capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
